HomeCompareABSCF vs VIG

ABSCF vs VIG: Dividend Comparison 2026

ABSCF yields 137.93% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABSCF wins by $16.42M in total portfolio value
10 years
ABSCF
ABSCF
● Live price
137.93%
Share price
$1.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16.45M
Annual income
$6,780,916.45
Full ABSCF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — ABSCF vs VIG

📍 ABSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABSCFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABSCF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABSCF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABSCF
Annual income on $10K today (after 15% tax)
$11,724.14/yr
After 10yr DRIP, annual income (after tax)
$5,763,778.98/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, ABSCF beats the other by $5,763,630.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABSCF + VIG for your $10,000?

ABSCF: 50%VIG: 50%
100% VIG50/50100% ABSCF
Portfolio after 10yr
$8.24M
Annual income
$3,390,545.82/yr
Blended yield
41.14%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABSCF buys
0
VIG buys
9
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$VIG▲ Buy$1,001 - $15,0002024-05-16
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002024-01-26
Lindsey Graham🏛 Senate$VIG▼ Sell$15,001 - $50,0002023-12-28
Ro Khanna🏢 House$VIG▼ Sell$15,001 - $50,0002023-05-04
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
K. Michael Conaway🏢 House$VIG▲ Buy$50,001 - $100,0002020-12-10
Joe Courtney🏢 House$VIG▼ Sell$1,001 - $15,0002020-10-09
K. Michael Conaway🏢 House$VIG▼ Sell$50,001 - $100,0002020-09-08
K. Michael Conaway🏢 House$VIG▲ Buy$15,001 - $50,0002020-05-19
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABSCFVIG
Forward yield137.93%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$16.45M$32.3K
Annual income after 10y$6,780,916.45$175.21
Total dividends collected$15.13M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ABSCF vs VIG ($10,000, DRIP)

YearABSCF PortfolioABSCF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$24,493$13,793.10$11,301$160.59+$13.2KABSCF
2$57,781$31,573.45$12,752$162.91+$45.0KABSCF
3$131,437$69,611.34$14,370$165.02+$117.1KABSCF
4$288,626$147,988.71$16,176$166.93+$272.4KABSCF
5$612,543$303,712.69$18,188$168.67+$594.4KABSCF
6$1,257,814$602,392.61$20,432$170.25+$1.24MABSCF
7$2,501,908$1,156,047.28$22,933$171.68+$2.48MABSCF
8$4,826,093$2,149,051.62$25,720$172.98+$4.80MABSCF
9$9,038,168$3,874,248.32$28,827$174.15+$9.01MABSCF
10$16,451,756$6,780,916.45$32,288$175.21+$16.42MABSCF

ABSCF vs VIG: Complete Analysis 2026

ABSCFStock

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Full ABSCF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this ABSCF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABSCF vs SCHDABSCF vs JEPIABSCF vs OABSCF vs KOABSCF vs MAINABSCF vs DGROABSCF vs NOBLABSCF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.